In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of...
In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin (AMRN -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking approval for Chemport, Inc. as an additional Vascepa active pharmaceutical ingredient supplier. The submission is part of the company's goal to expand and protect its manufacturing supply chain.
From other sites
at CNBC.com (Feb 28, 2014)
at CNBC.com (Oct 17, 2013)
at CNBC.com (Aug 22, 2013)
at CNBC.com (Mar 21, 2013)
at CNBC.com (Jan 17, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs